Claritev (CTEV) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue was $233.5 million, down 1.9% year-over-year, with a net loss of $576.7 million driven by a $553.7 million goodwill impairment charge.

• Adjusted EBITDA for Q2 2024 was $146.7 million, down 3.9% year-over-year, with a margin of 62.8%.

• Identified $6.2 billion in potential medical cost savings for payors and health plan sponsors, up 9% year-over-year and 8% sequentially.

• Closed 166 sales opportunities, adding $9.9 million in annual contract value and four new clients, including first sales in provider and value-based care markets.

• CFO transition plan announced, with a new CFO starting August 2024 and the outgoing CFO remaining as a strategic advisor through year-end.

Financial highlights

• Q2 2024 revenue declined by $4.5 million year-over-year, mainly due to a $11.4 million drop in Network-Based Services, partially offset by a $8.5 million increase in Analytics-Based Services.

• Adjusted EBITDA was $146.7 million, down 3.9% year-over-year and flat sequentially; margin was 62.8%.

• Net loss for Q2 2024 was $576.7 million, primarily due to a $553.7 million impairment charge.

• Operating cash flow for Q2 2024 was $18.5 million; free cash flow was negative $7.0 million.

• Ended Q2 2024 with $48.8 million in unrestricted cash and $4.5 billion in long-term debt.

Outlook and guidance

• Full-year 2024 revenue guidance revised to $935–$955 million, down from $1.0–$1.03 billion.

• Adjusted EBITDA guidance lowered to $580–$595 million; margin expected at ~62%.

• Q3 2024 guidance: revenue of $230–$245 million and adjusted EBITDA of $140–$155 million.

• Guidance revision reflects slower core business growth, delayed new product traction, and client attrition.

• Growth in the core business is expected to resume after mid-2025 as the attrition overhang clears.